Increased bone resorption has been demonstrated in preclinical models, including OVX, to accelerate cancer progression in bone [30–32] presumably via release of matrix-derived growth factors, (e.g., TGFβ, IGF, FGF, PDGF), which stimulate tumor growth and expression of osteolytic factors that perpetuate a feed-forward cycle of bone destruction [20]. The gene discussed is IGF1; the disease is cancer.